INITIATOR PHARMA: Q1 2023 REPORT

Regulatory

Business highlights in Q1 2023

  • In March the Company announced the completion of dosing of all 24 patients the the Phase IIa clinical trial with IP2018 and that preliminary results are expected end of Q2 2023.

Business highlights after this reporting period

  • Nothing to report

Financial Highlights

First Quarter (2023-01-01 – 2023-03-31)
Net revenue were TDKK 0 (0)
Operating loss, EBIT was TDKK -8,677 (-15,075)
Earnings per share was DKK –0.18 (-0.35)
Cash: TDKK 33,719 (26,352)
Solidity: 63% (52%)

Solidity: equity divided by assets.

The Board of Directors have decided that interim reports will be published in English only.

Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: [email protected]

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of two clinical stage assets – IP2015 and IP2018 – and two preclinical assets. The company is currently conducting a Phase 2b trial with IP2015 in erectile dysfunction of organic origin, and successfully completed a Phase 1 proof of principle trial in neuropathic pain in 2022. With IP2018 the company is conducting a Phase 2a trial for the treatment of erectile dysfunction of psychogenic origin.

Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Documents